Total trials
846
Active
163
Phase 3
30
Total enrollment
2,266,944
Pipeline matrix
Showing 40 of 43 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Rivaroxaban | — | — | — | — | 2 | ||
| Apixaban | — | — | — | — | 2 | ||
| Dalteparin Sodium | — | — | — | — | — | 1 | |
| Tinzaparin Sodium | — | — | — | — | — | 1 | |
| Enoxaparin Sodium | — | — | — | — | — | 1 | |
| Dabigatran Etexilate | — | — | — | — | — | 1 | |
| Foam sclerotherapy | — | — | — | — | 2 | ||
| Pembrolizumab 25 MG/ML [Keytruda] | — | — | — | — | — | 1 | |
| Erythropoietin | — | — | — | — | — | 1 | |
| XBD173 | — | — | — | 8 | |||
| Pembrolizumab | — | — | — | — | — | 3 | |
| Fostamatinib | — | — | — | — | — | 2 | |
| Modafinil | — | — | — | — | — | 1 | |
| EBX-102 | — | — | — | — | — | 1 | |
| Doxorubicin and Cisplatin | — | — | — | — | — | 1 | |
| tadalafil | — | — | — | — | — | 1 | |
| Investigational Medicinal Product | — | — | — | — | — | 1 | |
| Smart devices with Personalised data feedback and habit coaching | — | — | — | — | — | 1 | |
| Standard of Care | — | — | — | — | — | 1 | |
| Maralixibat | — | — | — | — | — | 1 | |
| Tezepelumab | — | — | — | — | — | 1 | |
| Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy | — | — | — | — | — | 1 | |
| FINGER 2.0 multidomain lifestyle-based intervention | — | — | — | — | — | 1 | |
| Semaglutide | — | — | — | — | 2 | ||
| SARS-CoV-2 Omicron EG.5.1 challenge agent 10^5 TCID50 | — | — | — | — | — | 1 | |
| SARS-CoV-2 Omicron EG.5.1 challenge agent 10^6 TCID50 | — | — | — | — | — | 1 | |
| SARS-CoV-2 Omicron EG.5.1 challenge agent 10^4 TCID50 | — | — | — | — | — | 1 | |
| Dostarlimab in Combination Antiretroviral Therapy | — | — | — | — | — | 1 | |
| ASTX727 | — | — | — | — | — | 1 | |
| Psilocybin 5 mg with cognitive behavioural therapy intervention | — | — | — | — | — | 1 | |
| Rituximab | — | — | — | — | 3 | ||
| Metformin | — | — | — | 3 | |||
| Hydrocortisone | — | — | — | — | 2 | ||
| Other | — | — | — | — | — | 1 | |
| Bisoprolol 2.5 mg | — | — | — | — | — | 1 | |
| Semaglutide Oral Product | — | — | — | — | — | 1 | |
| Rhinovirus-A16 | — | — | — | — | — | 1 | |
| FLUENZ | — | — | — | — | — | 1 | |
| Influenza challenge virus | — | — | — | — | — | 1 | |
| Pimonidazole hydrochloride | — | — | — | — | — | 1 |
3 more active programs hidden
Next readouts
- 2023-04-05
- 2024-12-01
- 2024-12-30
- 2025-01-31
- 2025-05-31
- 2025-07
- 2026-02-01
- 2026-02-01
- 2026-02-02
- 2026-03-26
Top conditions
- Asthma39
- Obesity31
- Heart Failure22
- COPD18
- Chronic Obstructive Pulmonary Disease17
- Breast Cancer13
- HIV13
- Stroke11
Frequently asked questions about Imperial College London
- How many clinical trials does Imperial College London have on ClinicalTrials.gov?
- Imperial College London is listed as the lead sponsor on 846 clinical trials in ClinicalTrials.gov, 163 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Imperial College London's trials are in Phase 3?
- 30 of Imperial College London's trials are in Phase 3, spread across 43 active drug programs.
- What therapeutic areas does Imperial College London focus on?
- Imperial College London's most-studied conditions on ClinicalTrials.gov are Asthma, Obesity, Heart Failure, COPD, Chronic Obstructive Pulmonary Disease.
- When are Imperial College London's next clinical trial readouts?
- Imperial College London has 10 upcoming primary-completion readouts tracked here; the soonest is “Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection”, expected around 2023-04-05.